Condition (MeSH)
Adrenocortical Adenoma
ClinicalTrials.gov lists 19 trials for Adrenocortical Adenoma or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Adrenocortical Adenoma itself; the rest are tagged with a narrower condition beneath it.
When did Adrenocortical Adenoma trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Adrenocortical Adenoma trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 8 |
| Observational | 9 |
How many Adrenocortical Adenoma trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Completed | 9 |
| Unknown status | 5 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Adrenocortical Adenoma trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
Which drugs are being tested for Adrenocortical Adenoma? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| BGG492 | 1 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Hypotensive Drugs | 1 |
| Biopsy | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Adrenocortical Adenoma trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Adrenal Adenoma | 3 | 1 |
| Angiomyolipoma | 1 | 1 |
| Ovarian cyst | 1 | 1 |
Which publications cover Adrenocortical Adenoma? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Impaired Cognitive Function in Patients With Autonomous Cortisol Secretion in Adrenal Incidentalomas. | The Journal of clinical endocrinology and metabolism | 2023 | Yes |
| Mortality Not Increased in Patients With Nonfunctional Adrenal Adenomas: A Matched Cohort Study. | The Journal of clinical endocrinology and metabolism | 2023 | Yes |
| Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population : A Cross-Sectional Study. | Annals of internal medicine | 2022 | Yes |
| Enhanced performance of a modified diagnostic test of primary aldosteronism in patients with adrenal adenomas. | European journal of endocrinology | 2022 | Yes |
| Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. | Endocrine pathology | 2022 | Yes |
Showing 5 of 40 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.